Modeling Is Not a Drug Approval Pathway: Why Merck Flunked Keytruda’s TNBC Advisory Panel

 
• By Sarah Karlin-Smith
  
photo illustration/shutterstock
Keytruda may have a long road ahead for its next approval after a stop at ODAC. • Source: photo illustration/Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers